Form 4: Checkpoint Therapeutics CEO James Oliviero Sells Shares to Cover Tax Obligations

Checkpoint Therapeutics CEO James Oliviero sold 15,090 shares of common stock on April 2, 2025, to cover tax withholding obligations related to the vesting of restricted shares.

Summary

• On April 2, 2025, James F. Oliviero, III, CEO, President, and Director of Checkpoint Therapeutics, Inc., sold 15,090 shares of common stock at a price of $4.04 per share.
• The sale was executed to satisfy tax withholding obligations related to the vesting of restricted shares.
• Oliviero had no discretion over the sale, which was transacted automatically according to company policy.
• Following the transaction, Oliviero beneficially owns 3,759,929 shares, including restricted common stock that vests over various time periods.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a transaction. The sale is related to tax obligations, which is a common occurrence.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be routine, covering tax obligations related to vested stock.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, although it is likely to be viewed as a routine transaction.

Key Dates

Keywords

Checkpoint Therapeutics, James Oliviero, stock sale, Form 4, insider trading, restricted stock, tax withholding, CKPT